DK1270595T3 - Anti-CCR4-antistof og dets fragment - Google Patents

Anti-CCR4-antistof og dets fragment

Info

Publication number
DK1270595T3
DK1270595T3 DK01908280T DK01908280T DK1270595T3 DK 1270595 T3 DK1270595 T3 DK 1270595T3 DK 01908280 T DK01908280 T DK 01908280T DK 01908280 T DK01908280 T DK 01908280T DK 1270595 T3 DK1270595 T3 DK 1270595T3
Authority
DK
Denmark
Prior art keywords
ccr4
antibody
fragment
antibody fragment
recombinant antibody
Prior art date
Application number
DK01908280T
Other languages
English (en)
Inventor
Kenya Shitara
Nobuo Hanai
Mikiko Sakurada
Akiko Furuya
Kazuyasu Nakamura
Rinpei Niwa
Kenji Shibata
Emi Hosaka
Motoo Yamasaki
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Application granted granted Critical
Publication of DK1270595T3 publication Critical patent/DK1270595T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
DK01908280T 2000-03-03 2001-03-02 Anti-CCR4-antistof og dets fragment DK1270595T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000059508 2000-03-03
JP2000401563 2000-12-28
PCT/JP2001/001656 WO2001064754A1 (fr) 2000-03-03 2001-03-02 Anticorps a recombinaison genique et son fragment

Publications (1)

Publication Number Publication Date
DK1270595T3 true DK1270595T3 (da) 2008-11-10

Family

ID=26586785

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01908280T DK1270595T3 (da) 2000-03-03 2001-03-02 Anti-CCR4-antistof og dets fragment

Country Status (15)

Country Link
US (4) US6989145B2 (da)
EP (2) EP1992644A1 (da)
JP (1) JP3926153B2 (da)
KR (1) KR100890873B1 (da)
CN (1) CN100455599C (da)
AT (1) ATE402192T1 (da)
AU (2) AU2001236073B2 (da)
CA (1) CA2401491C (da)
CY (1) CY1108397T1 (da)
DE (1) DE60134962D1 (da)
DK (1) DK1270595T3 (da)
ES (1) ES2309050T3 (da)
PT (1) PT1270595E (da)
SI (1) SI1270595T1 (da)
WO (1) WO2001064754A1 (da)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
EP2275540B1 (en) * 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
CA2424602C (en) 2000-10-06 2012-09-18 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-producing cell
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
BR0207857A (pt) * 2001-03-06 2004-03-23 Dow Chemical Co Célula de planta tendo uma função de adição de açúcar do tipo animal
PT1390389E (pt) 2001-04-26 2009-04-03 Biogen Idec Inc Anticorpos que bloqueiam o cripto e as utilizações dos mesmos
US7582299B2 (en) 2001-04-26 2009-09-01 Biogen Idec Ma Inc. Cripto-specific antibodies
JP4052515B2 (ja) * 2001-08-31 2008-02-27 協和醗酵工業株式会社 ヒト型ｃｄｒ移植抗体およびその抗体断片
AU2002258011B2 (en) * 2001-12-04 2009-01-08 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health Chimeric molecule for the treatment of TH2-like cytokine mediated disorders
WO2003072134A1 (fr) * 2002-02-28 2003-09-04 Kyowa Hakko Kogyo Co., Ltd. Diagnostics et therapeutiques pour la pneumonie interstitielle
US7691568B2 (en) 2002-04-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Antibody composition-containing medicament
WO2004072646A1 (en) * 2003-02-13 2004-08-26 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 5 (gpr5)
US7700097B2 (en) 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
FR2858235B1 (fr) 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
JP4219932B2 (ja) 2003-10-01 2009-02-04 協和発酵キリン株式会社 抗体の安定化方法及び安定化された溶液状抗体製剤
US20050287138A1 (en) * 2003-10-08 2005-12-29 Kyowa Hakko Kogyo Co., Ltd. CCR4-specific antibody composition
FR2861395B1 (fr) 2003-10-23 2006-02-17 Lab Francais Du Fractionnement Facteur viii viralement securise a faible teneur en multimeres superieurs
EP1702625B1 (en) * 2003-12-04 2010-11-03 Kyowa Hakko Kirin Co., Ltd. Medicine containing genetically modified antibody against chemokine receptor ccr4
JPWO2005053742A1 (ja) * 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
JP4943161B2 (ja) 2003-12-23 2012-05-30 ジェネンテック， インコーポレイテッド 新規抗ｉｌ１３モノクローナル抗体での癌の処置
US20060034841A1 (en) * 2004-06-07 2006-02-16 Kyowa Hakko Kogyo Co., Ltd. Method of depleting regulatory T cell
SG173313A1 (en) 2005-01-05 2011-08-29 Biogen Idec Inc Cripto binding molecules
WO2009001840A1 (ja) * 2007-06-25 2008-12-31 Forerunner Pharma Research Co., Ltd. ADCC活性又はCDC活性を有する抗Prominin-1抗体
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
JP5552630B2 (ja) * 2008-10-24 2014-07-16 学校法人 聖マリアンナ医科大学 Ｈｔｌｖ−ｉ関連脊髄症を治療または予防するための医薬、およびｈｔｌｖ−ｉ関連脊髄症の患者に対する抗体療法の効果を試験する方法
GB0909906D0 (en) 2009-06-09 2009-07-22 Affitech As Antibodies
CA2775350A1 (en) * 2009-09-24 2011-03-31 Seattle Genetics, Inc. Dr5 ligand drug conjugates
AU2011222012C1 (en) 2010-03-02 2015-02-26 Kyowa Kirin Co., Ltd. Modified antibody composition
US10266599B2 (en) 2010-12-07 2019-04-23 Cancer Research Technology Limited Antibodies which bind to the human CC chemokine receptor 4 and uses thereof
GB201020738D0 (en) 2010-12-07 2011-01-19 Affitech Res As Antibodies
AU2011343570B2 (en) 2010-12-16 2016-11-03 Genentech, Inc. Diagnosis and treatments relating to TH2 inhibition
PT2691417T (pt) 2011-03-29 2018-10-31 Roche Glycart Ag Variantes de fc de anticorpos
EP3626739A1 (en) 2011-06-24 2020-03-25 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US20130280282A1 (en) * 2012-04-24 2013-10-24 Daiichi Sankyo Co., Ltd. Dr5 ligand drug conjugates
MX365592B (es) * 2012-07-06 2019-06-07 Univ School St Marianna Medicine Anticuerpo para reducir células infectadas con el virus de htlv-1.
HUE056217T2 (hu) 2012-07-13 2022-02-28 Roche Glycart Ag Bispecifikus anti-VEGF/anti-ANG-2 antitestek és ezek alkalmazása szemészeti érbetegségek kezelésében
NZ756749A (en) 2013-09-13 2022-05-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
RU2016107435A (ru) 2013-09-13 2017-10-18 Дженентек, Инк. Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
EP3699196A1 (en) 2014-10-06 2020-08-26 Dana Farber Cancer Institute, Inc. Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof
JP2018524361A (ja) 2015-07-14 2018-08-30 協和発酵キリン株式会社 抗体と併用投与されるｉｄｏ阻害剤含有腫瘍治療剤
JP2019508222A (ja) 2015-12-22 2019-03-28 スリーエム イノベイティブ プロパティズ カンパニー 試料分配用のステム−ウェルフィルム
TWI784957B (zh) 2016-06-20 2022-12-01 英商克馬伯有限公司 免疫細胞介素
US20210113672A1 (en) * 2016-12-08 2021-04-22 Nantbio, Inc. Method of validating the triggering of an immune response to a neoepitope of a tumor with t-cells
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
EP3765500A2 (en) 2018-03-16 2021-01-20 Zoetis Services LLC Interleukin-31 monoclonal antibodies for veterinary use
MX2020009639A (es) 2018-03-16 2021-01-08 Zoetis Services Llc Vacunas de peptídos contra interleucina-31.
CN112203685A (zh) * 2018-03-29 2021-01-08 瑞美德生物医药科技有限公司 使用结合白细胞介素-17a(il-17a)的抗体的自身免疫紊乱和炎性紊乱的治疗
EP3883610A4 (en) 2018-11-20 2022-11-02 Cornell University MACROCYCLIC COMPLEXES OF RADIONUCLIDES AND THEIR USE IN CANCER RADIATION THERAPY

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US19341A (en) * 1858-02-16 Louis beauche
US160015A (en) * 1875-02-23 Improvement in devices for cutting out sheet-metal washers
US187930A (en) * 1877-02-27 Improvement in processes of preserving meat
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
JPH02257891A (ja) 1989-03-31 1990-10-18 Kyowa Hakko Kogyo Co Ltd 組換え動物細胞による蛋白質の製造
US5914110A (en) 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
JPH0853355A (ja) 1994-08-12 1996-02-27 Taisho Pharmaceut Co Ltd Ｉｌ−５産生抑制剤
GB9501683D0 (en) * 1995-01-27 1995-03-15 Glaxo Group Ltd Substances and their uses
US6498015B1 (en) * 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
WO1996040923A1 (en) * 1995-06-07 1996-12-19 Icos Corporation Macrophage derived chemokine and chemokine analogs
JP3946256B2 (ja) * 1995-09-11 2007-07-18 協和醗酵工業株式会社 ヒトインターロイキン５受容体α鎖に対する抗体
IL125658A0 (en) 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
KR20040031107A (ko) 1997-11-12 2004-04-09 에프. 호프만-라 로슈 아게 레티노이드 길항제를 이용한 제2형 ｔ-보조세포 중재면역질환의 치료
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
AU753131B2 (en) 1998-06-26 2002-10-10 Chugai Seiyaku Kabushiki Kaisha Remedies for hypercalcemic crisis
US6488930B1 (en) 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
US6245332B1 (en) * 1999-01-15 2001-06-12 The Board Of Trustees Of The Leland Stanford Junior University Modulation of systemic memory T cell trafficking
EP1050307A1 (en) * 1999-05-06 2000-11-08 Applied Research Systems ARS Holding N.V. CCR4 antagonists in sepsis
JP4052515B2 (ja) 2001-08-31 2008-02-27 協和醗酵工業株式会社 ヒト型ｃｄｒ移植抗体およびその抗体断片
US20050287138A1 (en) * 2003-10-08 2005-12-29 Kyowa Hakko Kogyo Co., Ltd. CCR4-specific antibody composition
EP1702625B1 (en) * 2003-12-04 2010-11-03 Kyowa Hakko Kirin Co., Ltd. Medicine containing genetically modified antibody against chemokine receptor ccr4
US20060034841A1 (en) * 2004-06-07 2006-02-16 Kyowa Hakko Kogyo Co., Ltd. Method of depleting regulatory T cell

Also Published As

Publication number Publication date
WO2001064754A1 (fr) 2001-09-07
US8197814B2 (en) 2012-06-12
EP1270595B1 (en) 2008-07-23
US20050187380A1 (en) 2005-08-25
CA2401491C (en) 2011-07-05
EP1992644A1 (en) 2008-11-19
AU2001236073B2 (en) 2006-10-19
EP1270595A4 (en) 2005-07-27
JP3926153B2 (ja) 2007-06-06
CY1108397T1 (el) 2014-02-12
AU3607301A (en) 2001-09-12
US6989145B2 (en) 2006-01-24
CN1407993A (zh) 2003-04-02
KR100890873B1 (ko) 2009-03-31
CA2401491A1 (en) 2001-09-07
SI1270595T1 (sl) 2008-12-31
US20120276090A1 (en) 2012-11-01
PT1270595E (pt) 2008-09-16
KR20020089377A (ko) 2002-11-29
ATE402192T1 (de) 2008-08-15
US7666418B2 (en) 2010-02-23
EP1270595A1 (en) 2003-01-02
CN100455599C (zh) 2009-01-28
DE60134962D1 (de) 2008-09-04
US20020098527A1 (en) 2002-07-25
ES2309050T3 (es) 2008-12-16
US8632996B2 (en) 2014-01-21
US20100221178A1 (en) 2010-09-02

Similar Documents

Publication Publication Date Title
DK1270595T3 (da) Anti-CCR4-antistof og dets fragment
EA200500497A3 (ru) ЧЕЛОВЕЧЕСКИЕ АНТИ-IFN-γ НЕЙТРАЛИЗУЮЩИЕ АНТИТЕЛА В КАЧЕСТВЕ СЕЛЕКТИВНЫХ ИНГИБИТОРОВ ПУТЕЙ IFN-γ
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
MXPA03000103A (es) Antigenos de streptococcus.
HK1084688A1 (en) Therapeutic human anti-il-1r1 monoclonal antibody
CY1108765T1 (el) ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
HK1087018A1 (en) Peptide-based passive immunization therapy for treatment of atherosclerosis
IL144265A0 (en) Use of antibodies for the vaccination against cancer
IT1307864B1 (it) Metodo diagnostico per il riconoscimento di neoplasie umane attraversola determinazione dell'isoforma ctn-c della tn-c, frammenti di
CY1107921T1 (el) Μεθοδος για την προγνωση της αθροιστικης επιβιωσης ασθενων
EP1808179A3 (en) Use of HSP20 for promoting wound healing and/or reducing scar formation
ATE444762T1 (de) Therapeutische zusammenseztungen zur toleranzinduktion
DK1313850T3 (da) Nucleinsyre og tilsvarende protein med navnet 85PB3 anvendelige til behandling og påvisning af cancer
ATE537257T1 (de) Mit iga-nephropathie assoziierte dns
WO2001079434A3 (fr) Nouveau polypeptide, signal peptidase humaine 10, et polynucleotide codant pour ce polypeptide
SE0202959D0 (sv) Peptide-Base passive immunization therapy for treatment of atherosclerosis
WO2001075021A3 (fr) Nouveau polypeptide, proteine humaine associee au transport de glucose 10, et polynucleotide codant pour ce polypeptide
WO2001075016A3 (fr) Nouveau polypeptide, tyrosinase humaine 16, et polynucleotide codant pour ce polypeptide
WO2001075010A3 (fr) Nouveau polypeptide, proteine humaine de transduction nucleaire 25 contenant un domaine structurel atp/gtp, et polynucleotide codant pour ce polypeptide
WO2001075006A3 (fr) Nouveau polypeptide, chaîne légere de protéine réseau 37, et polynucléotide codant pour ce polypeptide
WO2001075051A3 (fr) Nouveau polypeptide, proteine humaine 17 stag3 (antigene stromal), et polynucleotide codant pour ce polypeptide
ITPT20020011A0 (it) Sistema ottico per la misura dell'usurae dei parametri geometrici della linea di contatto in ambito ferroviario.
WO2001068693A8 (fr) Nouveau polypeptide, proteine humaine de reception cannabinoide 7, et polynucleotide codant pour ce polypeptide
UA2986U (uk) Спосіб лікування розсіяного склерозу